Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global hypophosphatasia treatment market is expected to be valued at US$ 16.13 Million in 2023. With the increasing alcohol consumption among people, the overall demand for hypophosphatasia treatment is projected to grow at a CAGR of 5.0% between 2023 and 2033, totaling around US$ 26.27 Million by 2033.
According to the analysis of Future Market Insights, the hypophosphatasia treatment market is expected to fuel over the analysis period, attributed to the factors such as the focus of pharmaceutical companies as well as research Institutes on studying and developing new methods for the treatment of hypophosphatasia. For instance, Asfotase alpha is being studied by Alexion Pharmaceuticals and is in phase 2 of clinical trials for the study to evaluate its pharmacokinetic and pharmacodynamics in adult participants with pediatric-onset hypophosphatasia.
Additionally, the current treatment of hypophosphatasia includes the use of Asfotase alpha, which was approved by the Food and Drug Administration in 2015. Asfotase alpha is the first approved medication for the treatment of perinatal, infantile, and juvenile-onset hypophosphatasia. Also, Asfotase alpha is a recombinant human alkaline phosphatase available for long-term enzyme replacement to treat the bone manifestation of the disease. Another treatment used to improve the symptoms of hypophosphatasia includes drugs like NSAIDs and Vitamin B6.
Data Points | Key Statistics |
---|---|
Hypophosphatasia Treatment Market Value 2023 | US$ 15.36 Million |
Hypophosphatasia Treatment Market Projected Value (2033) | US$ 26.27 Million |
Hypophosphatasia Treatment Market CAGR (2023 to 2033) | 5.0% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for hypophosphatasia treatment is projected to increase at a CAGR of 5.0% during the forecast period between 2023 and 2033, reaching a total of US$ 16.13 Million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 2.6%. According to Future Market Insights, a market research and competitive intelligence provider, the Hypophosphatasia Treatment market was valued at US$ 15.36 Million in 2022.
As per the statistics published by the National Organization for Rare Disorders, Inc., there is an estimated annual incidence of hypophosphatasia is 1 in every 100,000 births in Canada. Factors such as the growing special designation from the regulatory authorities for the treatment of hypophosphatasia, coupled with the high demand for novel treatment are anticipated to boost the growth of the hypophosphatasia market over the analysis period.
Moreover, the increase in the demand for disease-specific novel treatment is another key factor that is projected to escalate the market growth in the coming years. In addition, huge financial support to the researchers for developing novel interventions is expected to augment the market growth in the near future. Also, the surge in special designation from the regulatory authorities to offer treatment to patients as quickly as possible is propelling the revenue share of the hypophosphatasia treatment market.
Family History of Hypophosphatasia to Fuel the Market Growth
The severe perinatal and infantile forms of hypophosphatasia are inherited as autosomal recessive conditions. The patient receives one defective gene from each parent. Some more mild (childhood or adult) hypophosphatasia cases are also inherited this way. Other mild adult as well as odontohypophospatasia cases seem to be inherited in an autosomal dominant pattern (the patient gets just one defective gene, not two, transmitted from one of his/her parents).
In this form, mild hypophosphatasia can occur from generation to generation. The perinatal form of hypophosphatasia can often be detected during pregnancy by ultrasound and by measuring ALP activity in chorionic villus samples from amniocentesis. Individuals with hypophosphatasia and parents of children with hypophosphatasia are encouraged to seek genetic counseling to explain the likelihood and severity of hypophosphatasia recurring in their families. This is a major factor that is projected to boost the growth of the market during the forecast period.
Rise in Prevalence of Hypophosphatasia to Accelerate the Market Growth
The rising incidence of genetic disorders characterized by the abnormal development of bones and teeth leads to Hypophosphatasia. These abnormalities occur due to defective mineralization such as calcium and phosphorus. These minerals are required for proper hardness as well as strength. Defective mineralization results in bones becoming soft and more prone to fracture.
Hypophosphatasia symptoms can vary greatly from one person to another, sometimes even among members of the same family. The disease is caused by mutations in the tissue nonspecific alkaline phosphatase (ALPL) gene, which is also known as the TNSALP gene. Such mutations lead to low activity of the tissue nonspecific alkaline phosphatase enzyme. Depending on the specific form, HPP can be inherited in an autosomal recessive or autosomal dominant manner. Thus, this is another major factor that is anticipated to fuel market growth in the forthcoming years.
Patent Expiration of Major Brands to Restrain the Market Growth
Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is one of the major factors that is expected to hamper the growth of the Hypophosphatasia Treatment Market during the forecast period.
Moreover, the patent expiration of major brands, coupled with the low healthcare budget in some developing regions will also impede market growth in the near future.
Fewer Treatment Options to Limit the Market Growth
Lack of skilled professionals or trained expertise in this area, in low-and-middle class economies, will hinder the way of market growth over the analysis period. In addition, factors including fewer treatment options available are likely to limit the growth of the hypophosphatasia treatment market in the coming years.
Increase in R&D Proficiencies in the Region to Fuel the Market Growth
The hypophosphatasia treatment market in North America is expected to accumulate the highest market share of 46% in 2023. Factors such as increasing research & development activities from major market players, and an increase in product offerings, are anticipated to fuel the regional market growth over the analysis period.
In addition, greater affordability, coupled with an increase in demand for early treatment are other major factors that will propel the Hypophosphatasia treatment market in North America in the coming years. The region is expected to hold the highest CAGR of 4.9% during the forecast period.
Growing Demand for Hypophosphatasia Treatment in the Region to Fuel the Market Growth
The hypophosphatasia treatment market in Asia Pacific is expected to accumulate the highest market share of 44% in 2023. The Asia Pacific hypophosphatasia market is anticipated to register significant growth during the analysis period, attributed to factors such as an increase in the adoption of new products, and a rise in demand for hypophosphatasia treatment in emerging countries such as India and China.
Additionally, other factors including increasing awareness about the disease will also propel the market growth in Asia Pacific in the near future. The region is expected to hold the highest CAGR of 4.8% during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Odontohypophospatasia Segment to beat Competition in Untiring Market
On the basis of type, the global Hypophosphatasia Treatment market is dominated by the Odontohypophospatasia Segment, which accounts for a share of 48%. The segment is expected to hold a CAGR of 4.9% over the analysis period.
The high segment’s growth is attributed to factors such as a high number of patients with odontoid hypophosphatasia, which is characterized by loss of premature teeth in childhood or loss of teeth in adulthood.
Medication Segment to Drive the Hypophosphatasia Treatment Market
Based on treatment type, the medication segment is expected to witness a significant growth of 47% in 2022, and the trend is expected to continue during the forecast period, expanding at a rapid rate of 4.8% CAGR over the analysis period.
This growth is attributed to the launch of products for the treatment of hypophosphatasia from major manufacturers. For instance, in 2015, the US Food and Drug Administration (FDA) approved Strensiq (asfotase alfa) as the first approved medical treatment for infantile, perinatal, and juvenile-onset HPP.
Hospital Pharmacies Segment to Drive the Hypophosphatasia Treatment Market
Based on the Distribution Channel, the hospital pharmacies segment is expected to witness a significant growth of 46% in 2022, and the trend is expected to continue during the forecast period, expanding at a 4.7% CAGR over the analysis period.
The segment’s significant growth is attributed to the fact that most of the major hypophosphatasia treatment products are prescription products, which are available in hospital pharmacies.
Hypophosphatasia Treatment Market startup players are adopting various marketing strategies such as new product launches, geographical expansion, mergers and acquisitions, partnerships, and collaboration to identify the interest of potential patients and create a larger customer base.
Prominent players in the hypophosphatasia treatment market are Kirin Holdings Company, Vericel Corporation, Mereo BioPharma Group plc., Novartis AG, AM-Pharma B.V., Alexion, Bayer AG, Enobia Pharma, and Pfizer, Inc., among others.
Recent Developments:
Report Attribute | Details |
---|---|
Growth Rate | CAGR of 5.0% from 2023 to 2033 |
Market Value in 2023 | US$ 16.13 Million |
Market Value in 2033 | US$ 26.27 Million |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization & Pricing | Available upon Request |
As of 2022, the market for hypophospatasia treatment was valued at US$ 15.36 Million, as per FMI
By 2023-end, sales of Hypophosphatasia Treatment closed at a value of US$ 16.13 Million
From 2018 to 2022, Hypophospatasia Treatment demand expanded at a CAGR of 2.6%
From 2023 to 2033, Hypophosphatasia Treatment sales are expected to flourish at a CAGR of 5.0%
By 2033, the market value of Hypophospatasia Treatment is expected to reach US$ 26.27 Million
By Type, the Odontohypophospatasia segment constitutes the bulk of market share of 48% in 2022
By treatment type, the medication segment dominates the market with a share of 47% in 2022.
1. Executive Summary | Hypophosphatasia Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Odontohypophosphatasia 5.3.2. Pseudohypophosphatasia 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 6.3.1. Medication 6.3.1.1. Asfotase Alfa 6.3.1.2. Non-Steroidal Anti-Inflammatory Drugs 6.3.1.3. Calcitonin 6.3.1.4. Strensiq 6.3.2. Surgery 6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033 7.3.1. Hospitals 7.3.2. Pharmacies 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. Asia-Pacific 8.3.6. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The US 9.2.1.2. Canada 9.2.2. By Type 9.2.3. By Treatment Type 9.2.4. By End Users 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By Treatment Type 9.3.4. By End Users 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Type 10.2.3. By Treatment Type 10.2.4. By End Users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Treatment Type 10.3.4. By End Users 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Benelux 11.2.1.2. France 11.2.1.3. Germany 11.2.1.4. Italy 11.2.1.5. Nordic 11.2.1.6. Spain 11.2.1.7. The UK 11.2.1.8. Rest of Western Europe 11.2.2. By Type 11.2.3. By Treatment Type 11.2.4. By End Users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Treatment Type 11.3.4. By End Users 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Rest of Eastern Europe 12.2.2. By Type 12.2.3. By Treatment Type 12.2.4. By End Users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Treatment Type 12.3.4. By End Users 12.4. Key Takeaways 13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Australia 13.2.1.6. New Zealand 13.2.1.7. Rest of APAC 13.2.2. By Type 13.2.3. By Treatment Type 13.2.4. By End Users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Treatment Type 13.3.4. By End Users 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Type 14.2.3. By Treatment Type 14.2.4. By End Users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By Treatment Type 14.3.4. By End Users 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. The US 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Type 15.1.2.2. By Treatment Type 15.1.2.3. By End Users 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Type 15.2.2.2. By Treatment Type 15.2.2.3. By End Users 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Type 15.3.2.2. By Treatment Type 15.3.2.3. By End Users 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Type 15.4.2.2. By Treatment Type 15.4.2.3. By End Users 15.5. Benelux 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Type 15.5.2.2. By Treatment Type 15.5.2.3. By End Users 15.6. France 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Type 15.6.2.2. By Treatment Type 15.6.2.3. By End Users 15.7. Germany 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Type 15.7.2.2. By Treatment Type 15.7.2.3. By End Users 15.8. Italy 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Type 15.8.2.2. By Treatment Type 15.8.2.3. By End Users 15.9. Nordic 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Type 15.9.2.2. By Treatment Type 15.9.2.3. By End Users 15.10. Spain 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Type 15.10.2.2. By Treatment Type 15.10.2.3. By End Users 15.11. The UK 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Type 15.11.2.2. By Treatment Type 15.11.2.3. By End Users 15.12. Poland 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Type 15.12.2.2. By Treatment Type 15.12.2.3. By End Users 15.13. Russia 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Type 15.13.2.2. By Treatment Type 15.13.2.3. By End Users 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Type 15.14.2.2. By Treatment Type 15.14.2.3. By End Users 15.15. Malaysia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Type 15.15.2.2. By Treatment Type 15.15.2.3. By End Users 15.16. Singapore 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Type 15.16.2.2. By Treatment Type 15.16.2.3. By End Users 15.17. Thailand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Type 15.17.2.2. By Treatment Type 15.17.2.3. By End Users 15.18. Australia 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Type 15.18.2.2. By Treatment Type 15.18.2.3. By End Users 15.19. New Zealand 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Type 15.19.2.2. By Treatment Type 15.19.2.3. By End Users 15.20. GCC Countries 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Type 15.20.2.2. By Treatment Type 15.20.2.3. By End Users 15.21. South Africa 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Type 15.21.2.2. By Treatment Type 15.21.2.3. By End Users 15.22. Israel 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Type 15.22.2.2. By Treatment Type 15.22.2.3. By End Users 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Type 16.3.3. By Treatment Type 16.3.4. By End Users 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. PuREC 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. AstraZeneca 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Aruvant Sciences 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. AM-Pharma 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Rallybio 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Biometrix 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Cook Medical 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Grena 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Redax 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Lung Therapeutics, Inc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Western Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 15: Western Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 16: Western Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: Eastern Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 19: Eastern Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 20: Eastern Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: APAC Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 23: APAC Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 24: APAC Market Value (US$ Million) Forecast by End Users, 2018 to 2033 Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033 Table 27: MEA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033 Table 28: MEA Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by End Users, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 17: Global Market Attractiveness by Type, 2023 to 2033 Figure 18: Global Market Attractiveness by Treatment Type, 2023 to 2033 Figure 19: Global Market Attractiveness by End Users, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Type, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by End Users, 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 37: North America Market Attractiveness by Type, 2023 to 2033 Figure 38: North America Market Attractiveness by Treatment Type, 2023 to 2033 Figure 39: North America Market Attractiveness by End Users, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Type, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by End Users, 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Type, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Treatment Type, 2023 to 2033 Figure 59: Latin America Market Attractiveness by End Users, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Western Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 62: Western Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 63: Western Europe Market Value (US$ Million) by End Users, 2023 to 2033 Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Western Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 71: Western Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 74: Western Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 77: Western Europe Market Attractiveness by Type, 2023 to 2033 Figure 78: Western Europe Market Attractiveness by Treatment Type, 2023 to 2033 Figure 79: Western Europe Market Attractiveness by End Users, 2023 to 2033 Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: Eastern Europe Market Value (US$ Million) by Type, 2023 to 2033 Figure 82: Eastern Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 83: Eastern Europe Market Value (US$ Million) by End Users, 2023 to 2033 Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 97: Eastern Europe Market Attractiveness by Type, 2023 to 2033 Figure 98: Eastern Europe Market Attractiveness by Treatment Type, 2023 to 2033 Figure 99: Eastern Europe Market Attractiveness by End Users, 2023 to 2033 Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033 Figure 101: APAC Market Value (US$ Million) by Type, 2023 to 2033 Figure 102: APAC Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 103: APAC Market Value (US$ Million) by End Users, 2023 to 2033 Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: APAC Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 109: APAC Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 110: APAC Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 111: APAC Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 112: APAC Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 113: APAC Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 114: APAC Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 115: APAC Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 116: APAC Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 117: APAC Market Attractiveness by Type, 2023 to 2033 Figure 118: APAC Market Attractiveness by Treatment Type, 2023 to 2033 Figure 119: APAC Market Attractiveness by End Users, 2023 to 2033 Figure 120: APAC Market Attractiveness by Country, 2023 to 2033 Figure 121: MEA Market Value (US$ Million) by Type, 2023 to 2033 Figure 122: MEA Market Value (US$ Million) by Treatment Type, 2023 to 2033 Figure 123: MEA Market Value (US$ Million) by End Users, 2023 to 2033 Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033 Figure 129: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033 Figure 130: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033 Figure 131: MEA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033 Figure 132: MEA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033 Figure 133: MEA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033 Figure 134: MEA Market Value (US$ Million) Analysis by End Users, 2018 to 2033 Figure 135: MEA Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033 Figure 136: MEA Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033 Figure 137: MEA Market Attractiveness by Type, 2023 to 2033 Figure 138: MEA Market Attractiveness by Treatment Type, 2023 to 2033 Figure 139: MEA Market Attractiveness by End Users, 2023 to 2033 Figure 140: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports